Display options
Cite
Umeda K, Miyamura T, Yamada K, et al. Clinical outcome of patients with recurrent or refractory localized Ewing's sarcoma family of tumors: A retrospective report from the Japan Ewing Sarcoma Study Group. Cancer Rep (Hoboken). 2021;4(3):e1329doi: 10.1002/cnr2.1329.
Umeda, K., Miyamura, T., Yamada, K., Sano, H., Hosono, A., Sumi, M., Okita, H., Kumamoto, T., Kawai, A., Hirayama, J., Jyoko, R., Sawada, A., Nakayama, H., Hosoya, Y., Maeda, N., Yamamoto, N., Imai, C., Hasegawa, D., Chin, M., Ozaki, T. (2021). Clinical outcome of patients with recurrent or refractory localized Ewing's sarcoma family of tumors: A retrospective report from the Japan Ewing Sarcoma Study Group. Cancer reports (Hoboken, N.J.), 4(3), e1329. https://doi.org/10.1002/cnr2.1329
Umeda, Katsutsugu, et al. "Clinical outcome of patients with recurrent or refractory localized Ewing's sarcoma family of tumors: A retrospective report from the Japan Ewing Sarcoma Study Group." Cancer reports (Hoboken, N.J.) vol. 4,3 (2021): e1329. doi: https://doi.org/10.1002/cnr2.1329
Umeda K, Miyamura T, Yamada K, Sano H, Hosono A, Sumi M, Okita H, Kumamoto T, Kawai A, Hirayama J, Jyoko R, Sawada A, Nakayama H, Hosoya Y, Maeda N, Yamamoto N, Imai C, Hasegawa D, Chin M, Ozaki T. Clinical outcome of patients with recurrent or refractory localized Ewing's sarcoma family of tumors: A retrospective report from the Japan Ewing Sarcoma Study Group. Cancer Rep (Hoboken). 2021 Jun;4(3):e1329. doi: 10.1002/cnr2.1329. Epub 2021 Jan 16. PMID: 33452866; PMCID: PMC8222563.
Copy Download .nbib Format: NLM
Share it on

Cancer Rep (Hoboken). 2021 Jun;4(3):e1329. doi: 10.1002/cnr2.1329. Epub 2021 Jan 16.

Clinical outcome of patients with recurrent or refractory localized Ewing's sarcoma family of tumors: A retrospective report from the Japan Ewing Sarcoma Study Group.

Cancer reports (Hoboken, N.J.)

Katsutsugu Umeda, Takako Miyamura, Kenji Yamada, Hideki Sano, Ako Hosono, Minako Sumi, Hajime Okita, Tadashi Kumamoto, Akira Kawai, Junya Hirayama, Ryoji Jyoko, Akihisa Sawada, Hideki Nakayama, Yosuke Hosoya, Naoko Maeda, Nobuyuki Yamamoto, Chihaya Imai, Daiichiro Hasegawa, Motoaki Chin, Toshifumi Ozaki,

Affiliations

  1. Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  2. Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan.
  3. Department of Orthopedic Surgery, Okazaki City Hospital, Okazaki, Japan.
  4. Department of Pediatric Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  5. Department of Pediatric Oncology, Fukushima Medical University, Fukushima, Japan.
  6. Department of Radiation Oncology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan.
  7. Department of Pathology, Keio University School of Medicine, Tokyo, Japan.
  8. Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan.
  9. Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan.
  10. Department of Pediatrics, Mie University Graduate School of Medicine, Tsu, Japan.
  11. Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  12. Department of Hematology/Oncology, Osaka Women's and Children's Hospital, Izumi, Japan.
  13. Department of Pediatrics, National Hospital Organization, Kyusyu Cancer Center, Fukuoka, Japan.
  14. Department of Pediatrics, St. Luke's International Hospital, Tokyo, Japan.
  15. Department of Pediatrics, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
  16. Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
  17. Department of Pediatrics, Niigata University Graduate School of Medicine and Dental Sciences, Niigata, Japan.
  18. Department of Hematology and Oncology, Children's Cancer Center, Kobe Children's Hospital, Kobe, Japan.
  19. Department of Pediatrics and Child Health, Nihon University Itabashi Hospital, Tokyo, Japan.

PMID: 33452866 PMCID: PMC8222563 DOI: 10.1002/cnr2.1329

Abstract

BACKGROUND: Patients with Ewing's sarcoma family of tumors (ESFT) who experience relapse or progression have a poor prognosis.

AIM: This study aimed to identify the prognostic and therapeutic factors affecting overall survival (OS) of patients with recurrent or refractory localized ESFT.

METHODS AND RESULTS: Thirty-eight patients with localized ESFT who experienced first relapse or progression between 2000 and 2018 were retrospectively reviewed. The 5-year OS rate of the entire cohort was 48.3% (95% confidence interval, 29.9%-64.5%). Multivariate analysis of OS identified time to relapse or progression, but not stem cell transplantation (SCT), as the sole independent risk factor (hazard ratio, 35.8; P = .002). Among 31 patients who received salvage chemotherapy before local treatment, 21 received chemotherapy regimens that are not conventionally used for newly diagnosed ESFT. The objective response rate to first-line salvage chemotherapy was 55.2% in the 29 evaluable patients. Time to relapse or progression was significantly associated with response to first-line salvage chemotherapy (P = .006).

CONCLUSIONS: The present study fails to demonstrate significant clinical benefit of SCT for recurrent or refractory localized ESFT. Recently established chemotherapy regimens may increase the survival rate of patients with recurrent or refractory localized ESFT while attenuating the beneficial effect of SCT.

© 2020 The Authors. Cancer Reports published by Wiley Periodicals LLC.

Keywords: Ewing's sarcoma family of tumors; chemotherapy; progression; relapse; stem cell transplantation

References

  1. Pediatr Blood Cancer. 2011 Oct;57(4):549-53 - PubMed
  2. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  3. Pediatr Blood Cancer. 2020 May;67(5):e28194 - PubMed
  4. J Clin Oncol. 2005 Jul 1;23(19):4354-62 - PubMed
  5. Pediatr Blood Cancer. 2008 Sep;51(3):334-8 - PubMed
  6. Pediatr Blood Cancer. 2014 Aug;61(8):1382-6 - PubMed
  7. Med Pediatr Oncol. 2003 Mar;40(3):141-7 - PubMed
  8. Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):168-77 - PubMed
  9. Lancet Oncol. 2010 Feb;11(2):184-92 - PubMed
  10. J Clin Oncol. 2012 Nov 20;30(33):4148-54 - PubMed
  11. Pediatr Blood Cancer. 2012 Nov;59(5):854-8 - PubMed
  12. Pediatr Blood Cancer. 2006 Nov;47(6):795-800 - PubMed
  13. J Clin Oncol. 2004 Jul 15;22(14):2873-6 - PubMed
  14. Bone Marrow Transplant. 2008 May;41(10):867-72 - PubMed
  15. N Engl J Med. 2003 Feb 20;348(8):694-701 - PubMed
  16. J Clin Oncol. 2011 Dec 1;29(34):4541-7 - PubMed
  17. Pediatr Blood Cancer. 2005 Apr;44(4):338-47 - PubMed
  18. Cancer. 2002 Jan 15;94(2):561-9 - PubMed
  19. Oncotarget. 2017 Jan 17;8(3):5523-5539 - PubMed
  20. Ann Oncol. 2003 Nov;14(11):1654-9 - PubMed
  21. Bone Marrow Transplant. 2013 Mar;48(3):452-8 - PubMed
  22. Cancer Rep (Hoboken). 2021 Jun;4(3):e1329 - PubMed
  23. Pediatr Blood Cancer. 2009 Dec;53(6):1029-34 - PubMed
  24. Ann Oncol. 2000 Nov;11(11):1451-62 - PubMed
  25. Cancer. 1996 Aug 15;78(4):892-900 - PubMed

Publication Types